Bide Pharmatech (SH:688073) Sou Hu Cai Jing·2025-10-15 20:32Core Viewpoint - Bid Pharma (688073) is actively managing its financial risks through foreign exchange hedging and optimizing the use of idle funds from its IPO, which reflects a strategic approach to enhance financial stability and operational efficiency [1][2][3] Trading Information Summary - As of October 15, 2025, Bid Pharma's stock closed at 68.47 CNY, up by 3.66%, with a turnover rate of 1.71%, a trading volume of 7,414 shares, and a transaction value of 50.07 million CNY [1] - On the same day, the net inflow of main funds was 28.05 thousand CNY, accounting for 0.56% of the total transaction value, while retail investors saw a net inflow of 721.24 thousand CNY, representing 14.4% of the total [1] Company Announcements Summary - Bid Pharma plans to conduct foreign exchange hedging to mitigate currency fluctuation risks due to its import and export operations, with a maximum contract value of 600 million CNY and a margin and premium not exceeding 20 million CNY, funded by its own resources [1] - The company has established a foreign exchange risk management system and has received approval from its board for this hedging activity, which is valid for 12 months [1] - Additionally, Bid Pharma intends to utilize up to 200 million CNY of temporarily idle funds from its IPO for cash management, focusing on safe, liquid, and short-term investment products [2] - This cash management plan has also been approved by the company's board and is expected to enhance the efficiency of fund utilization without affecting the ongoing investment projects [2]